Search Results

The multimillion-dollar collaboration will develop small molecule drugs against undisclosed targets.

Plus, how the geopolitical tensions with China will affect U.S. biopharma

GRO Biosciences Inc., an emerging biotechnology company leveraging synthetic biology to expand the amino acid alphabet and deliver on the promise of protein therapeutics, announced the expansion of its leadership with the hire of Tracey Lodie, PhD as Chief Development Officer.

A day after inking an AI deal with Alphabet’s Isomorphic Labs, Novartis is back at it, acquiring Calypso Biotech and tying up with Shanghai Argo in two RNA-i-focused pacts.

On Sunday, ahead of the J.P. Morgan Healthcare Conference, Alphabet’s artificial intelligence startup Isomorphic Labs secured its first pharma partnerships with Eli Lilly and Novartis worth nearly $3 billion.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).

Lophos Holdings Inc. (CSE: MESC) (“Lophos” or the “Company”), a Canadian bioscience company focused on the cultivation and sale of Lophophora williamsii (“Peyote”) and ThreeD Capital Inc. (CSE: IDK) (OTCQB: IDKFF) (“ThreeD”), a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, are pleased to announce the completion of its previously announced Securities Purchase Agreement (the “Agreement”).

Vivos Inc. (OTCQB: RDGL), Vivos Inc. filed the application for an Investigational Device Exemption (“IDE”).

Merit Medical Systems, Inc., a global leader of healthcare technology, announced it has executed an asset purchase agreement with EndoGastric Solutions, Inc. for a total cash consideration of approximately $105 million.